Immix Biopharma, Inc.
IMMX
$8.18
$0.172.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.35% | 20.91% | 26.31% | 37.48% | 53.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.11% | 4.28% | 17.78% | 13.31% | 40.48% |
| Operating Income | -32.11% | -4.28% | -17.78% | -13.31% | -40.48% |
| Income Before Tax | -35.75% | -6.92% | -20.23% | -13.42% | -39.10% |
| Income Tax Expenses | -8.05% | -2.87% | 19.41% | 40.00% | 55.30% |
| Earnings from Continuing Operations | -35.67% | -6.90% | -20.22% | -13.46% | -39.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -100.00% | -94.22% | -49.85% |
| Net Income | -36.21% | -7.64% | -21.58% | -14.78% | -40.11% |
| EBIT | -32.11% | -4.28% | -17.78% | -13.31% | -40.48% |
| EBITDA | -31.22% | -3.42% | -17.24% | -13.00% | -40.32% |
| EPS Basic | -12.05% | 9.31% | 7.31% | 23.21% | 11.08% |
| Normalized Basic EPS | -12.45% | 8.87% | 6.64% | 22.71% | 10.79% |
| EPS Diluted | -12.05% | 9.31% | 7.31% | 23.21% | 11.08% |
| Normalized Diluted EPS | -12.45% | 8.87% | 6.64% | 22.71% | 10.79% |
| Average Basic Shares Outstanding | 18.55% | 17.16% | 28.18% | 49.01% | 60.49% |
| Average Diluted Shares Outstanding | 18.55% | 17.16% | 28.18% | 49.01% | 60.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |